Evaluation of the Antifungal Activity of Fluconazole Nanovesicles Against *Aspergillus fumigatus*

Ahmed L. Osman¹*, Abd Elgadir A. Altoum¹, Devapriya Finney Shadroch¹, Asaad MA. Babker¹, Hesham Elashmouny², Nourhan Khaled Hassan², Rania Moataz El-Dahmy³, Mohamed Haider⁴,⁵ and Ibrahim Elsayed²,⁶

¹Department of Medical Laboratory Sciences, College of Health Sciences, Gulf Medical University. Ajman, United Arab Emirates.
²Department of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman, United Arab Emirates.
³Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6 University, Cairo, Egypt.
⁴Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, 27272, Sharjah, United Arab Emirates.
⁵Research Institute of Medical and Health Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates.
⁶Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.

*Corresponding Author E-mail: dr.ahmed@gmu.ac.ae

https://dx.doi.org/10.13005/bpj/2840

(Received: 30 October 2023; accepted: 14 December 2023)

Fluconazole is potent triazole drug used as effectively anti-fungal for treating a variety of local and systemic fungal infections. This drug is sparingly soluble in water. The objective of this research was to statistically optimize nanovesicular formulations contain fluconazole to improve its antifungal effect. The nanovesicular formulations were composed of Tween® 80, cetyl alcohol, and chitosan. The prepared nanovesicular formulations were investigated for their zeta potential, polydispersity index, particle size, and encapsulation efficiency. The nanovesicular that has been optimized formulation was consist of tween/cetyl alcohol ratio of 15:1 and 0.1% chitosan. Additionally, the optimized formulation increased significantly in fluconazole release ratio and extent in comparison to the suspension form of the drug. The find that fluconazole nanovesicles had a better effect and lower MIC when compared to the aqueous fluconazole suspension. Finally, the optimized nanovesicles can be considered a promising nanocarrier for delivery of fluconazole to increase its systemic antifungal efficacy.

**Keywords:** Antifungal Activity; Fluconazole; Central Composite Design; In Vitro Release; Nanovesicles.

Rhinosinusitis occurs when the mucosa of the nasal and paranasal sinuses is inflamed¹. It may be infectious or non-infectious due to immunological or non-allergic causes. Infectious rhinosinusitis is caused by fungal pathogens such as Bipolaris, Curvularia, and Aspergillus species². The most prevalent causative agent appears to be Aspergillus. The diagnosis is histological, based on allergic mucin exhibiting fungal components in Gomori’s methenamine silver staining method.
The diagnosed Aspergillus fumigatus is tested by various methods to identify the minimum inhibitory concentration (MIC) of fluconazole. One of the most common fungal isolates causing sinusitis is Aspergillus fumigatus. Surgical debridement followed by prolonged oral antifungal therapy results in chances of attaining renal impairment.

Fungal rhinosinusitis demands immediate attention, as its urgency necessitates swift initiation of both aggressive antifungal therapy and prompt surgical intervention to effectively address and mitigate the potentially severe consequences of this condition.

Fluconazole is a triazole antifungal medication employed for the treatment of various local and systemic fungal infections. It functions as an inhibitor of ergosterol, disrupting the integrity and fluidity of the fungal cell membrane, thereby impeding fungal growth. It exhibits limited solubility in water and boasts a remarkable 90% absolute oral bioavailability. The recommended oral dosage typically ranges from 50 to 400 mg, dependent on the specific pathological conditions.

Nanovesicles are commonly utilized as carriers or targeting vehicles for active substances within various body organs and tissues. These nanovesicles prepared in different forms, including micelles, cubosomes, noisomes, liposomes, transferosomes, and ethosomes. All serve as a versatile platform for enhancing the drug characteristics such as stability, solubility, and release characteristics, and overall bioavailability. The nanovesicle has been fine-tuned to be compatible with multiple administration routes, include ocular, transdermal, oral, parenteral, and nasal routes. Furthermore, specialized adaptations have been made to create vector oriented nanovesicle designed to target drugs to specific locations such as the colon, brain, liver, or tumors.

This study was aiming to determine the appropriate range of nanovesicles loaded with fluconazole to be directly exposed to the ATCC strains of Aspergillus fumigatus. This is to estimate the MIC of the antifungal agent to determine the minimal dosage of the drug to be administered to the infected individual rescuing them from the renal impairments that could occur.

**MATERIAL AND METHODS**

**Materials**

Fluconazole was provided as a gift from Julphar (Gulf Pharmaceutical Industries), United Arab Emirates. Cetyl alcohol and tween 80 was purchased form Sigma–Aldrich, Co. (St. Lois, United States). Other chemical materials of the analytical grade used were not purified further.

**Fluconazole nanovesicles Preparation**

A modified thin film hydration process was used to prepare the nanovesicles. In a nutshell, fluconazole, Tween 80, in addition to cetyl alcohol were precisely measured, dissolved in 2/1, v/v mixture of methanol and chloroform 10 mL, and placed in 250 mL flask round bottom. The rotary evaporator machine (Heidolph, Rotavapor, VV2000) was then employed under vacuum conditions, evaporating the organic solvent mixture at 60 °C and 150 rpm for 20 minutes. The resulting thin film on the wall was hydrated with a 10 mL of the low molecular weight chitosan solution in 0.1 M acetic acid under normal pressure. To prevent aggregation, the prepared nano-vesicles underwent sonication in an ultrasonic bath from (SH 150-41, PCI Analytic Pvt, Ltd) for a period of 1 minute.

**Statistical Designing**

The research employed central composite design with Design Expert® 7 software (Version 7. Stat_Ease Inc, MN) to investigate the impact of formulation variables on the characteristics of nanovesicles. Two independent factors, namely Tween/Cetyl with ratio (’l) and chitosan ratio (’2), were examined. The response tracked included particle size (PS, Yl), polydispersity index (PDI, Y2), zeta potential (ZP, Y3), and encapsulation efficiency (EE, Y4). Additionally, desirability value was calculated to aid in selecting the optimized formula.

**Characterization of the prepared fluconazole nanovesicle**

**Analysis of particle polydispersity index, zeta potential and the size**

The Zeta sizer (Nano ZS, Malvern Instrument, Malvern, United Kingdom) employed dynamic scattering of light for analyzing the polydispersity index (PDI), zeta potential (ZP), and particle size (PS) of the nano vesicular
formulations. Prior to analysis, dilution of samples from each formulation were performed to the point of haziness.

**Assessment of the encapsulation effectiveness of the formulated fluconazole nanovesicle**

Nano-vesicles loaded with fluconazole underwent centrifugation at 20,000 revolutions per minute for 1 hour at 40°C using a high-speed cool centrifuge (Andres Hetich GmbH and Co. KG, Tutlingen, Germany) to separate them from the un-encapsulated drug. The fluconazole concentration in the supernatant was determined by analyzing it with a UV-spectrophotometer (Shimadzu, Tokyo, Japan) according to previously established curve of calibration.

**Drug release from nanovesicular formulations in an in-vitro setting**

The release of the drug from the optimized nano vesicular formulation in addition to the drug suspensions were assessed utilizing the reverse dialysis method using a USP II dissolution machine (Pharm Test, Hainburg, Germany). A phosphate buffer (pH 6.6) of 900 mL served as the dissolution medium. Dialysis bags having a cut-off molecular weight of 12-14 kDa were filled with 3 mL of dissolution media. The speed of the rotation was set to 50 revolutions per minute, at 37 ± 1°C. Samples were collected at specified time intervals up to 240 minutes, and the concentration of the drug was analyzed using spectrophotometer at the predetermined wavelength set at 530 nm.

**Broth Microdilution Method**

Out of nine fluconazole nanovesicle prepared, one (F2) is tested against aqueous suspension of the drug. Both the aqueous suspension and nanovesicle forms of fluconazole were mixed with RPMI 1640 medium containing L-glutamine lacking bicarbonate. The pH of the mixture was adjusted to 7.0 by using (0.165 M.MOPS solution by Sigma Company). Serial dilution of the fluconazole were then prepared in nine microtiter plate wells, ranging from 1.0 to 0.2 mg/ml. Each well received 100 µl of the diluted fungal suspensions along with 100 µl of the fluconazole solution, resulting in a serial of diluted fluconazole concentrations. In order to ensure the accuracy of the experiment, each set was subjected to growth and sterile controls as part of the experimental procedure.

The microtiter plate was subsequently incubated at 35°C, and after 48 hours, they were examined to determine the Minimum Inhibitory Concentration (MIC). The MICs interpretation was the drug concentration at which 50% inhibition of growth was observed. Microscopic examination was used to determine the MICs, specifically identifying the lowest fluconazole concentration that led to morphological abnormality of the fungal hyphae characterized by short, numerous branching.

**Agar dilution technique**

Fluconazole was prepared in serial dilution in a molten medium that had been equilibrated to a temperature of 50°C. This medium consisted of RPMI 1640 with 2% glucose (sourced from Sigma Company) and 1.5% Agar. The purpose of this dilution was to create a series of drug concentrations. Subsequently, one milliliter of this mixture was dispensed into each well of a 12-well cell culture plate with a flat bottom and kept for solidification. In the middle of each well, 10 µl of the conidial suspension was introduced. To serve as a control, organism-free wells were included.
Minimal Inhibitory Concentrations (MICs) for mold fungi were examined after incubation for 48 h at a temperature of 35°C. The MICs were determined as the lowest drug concentration that effectively inhibits the fungal growth on the solid agar medium.

**Galactomannan (GM) antigen release method**

Alexander Imhof devised a Galactomannan antigen release method to assess the growth of the fungi independently of colony characteristics or growth density. This approach was selected because literature had indicated that Galactomannan is released in the growing media in quantities that correlate with the fungal burden. The microtiter plate was prepared using antifungal substances and fungal samples following the same procedure as the broth microdilution method described earlier. After incubating for 24 hours at a temperature of 35°C. From each well, 5 µl of the liquid was added to 5 ml of saline making overall dilution 1:1,000 ratio. The released GM was quantified using an enzyme immunoassay, specifically the GM Test Fungiopert Aspergillus Galactomannan ELISA Detection Kit, following the instructions of the manufacturer.

Next, 50 µl of these dilutions were transferred to microtiter plate wells that had been sensitized with EB-A2 monoclonal antibody, which targets Aspergillus Galactomannan. The microtiter plate was then placed in the incubator at 37°C for 90 minutes. Following this incubation, the microtiter plates washed, then 100 µl of a buffer solution contain ortho-phenylenediamine dihydro-chloride was added. The microtiter plates were placed in the incubator for an additional 30 minutes in the absence of light at room temperature, before 100 µl of a 1.5 M. sulfuric acid solution was added to halt the reaction. The reading of the optical density (OD) was taken at 450 nm.

The optical density index was determined by dividing the optical density of each sample by the optical density of a control sample that contain 1 ng of Galactomannan /ml. The rate between the Galactomannan indices in the samples and those in the controls were computed, and the concentration of the drug at which this ratio approached 0.5 is determined as a Minimum Inhibitory Concentration (MIC).

**RESULTS AND DISCUSSION**

**Effect of formulations factors on particle size (PS)**

The particle size measurements of the fluconazole nanovesicles prepared varied between

---

![Fig. 1](image-url). Response surface plots for the effects of tween/cetyl alcohol (T/C) ratio (‘1) and chitosan % (‘2) on the particle size (a), polydispersity index (b), zeta potential (c), and encapsulation efficiency % (d) of fluconazole nanovesicular formulations.
The equation for calculating the particle size analysis was:

\[
\text{Particle size (PS)} = 633.38 - 114.83 X_1 + 1.67 X_2
\]

Figure 1A shows that only tween/cetyl ratio (X1) significantly affected the PS values of the prepared nanovesicular formulations. Where the PS values were significantly decreased with increasing the tween/cetyl ratio. This could be attributed to the effect of tween 80 in reducing the interfacial tension between the nanovesicular surface and the surrounding aqueous medium. Additionally, the prepared nanovesicles were stabilized and protected from aggregation by the steric hindrance of the used surfactant. These findings are consistent with that published by Elsayed et al., who investigated the effect of tween 80 concentration on the vesicle size of rosuvastatin calcium elastic nanovesicles.

The values of the particle size (PS), polydispersity index (PDI), zeta potential (ZP), and encapsulation efficiency (EE) of the prepared nanovesicular formulations is published in table 1 (part 1 of this project) by Ahmed et al.

**Effect of formulations factors on polydispersity index (PDI)**

The polydispersity index (PDI) measurement of the prepared fluconazole nanovesicle varied from 0.152 to 1. As illustrated by Ahmed et al. The derived equation used for the PDI analysis was:

\[
PDI = 0.66 - 0.33 X_1 - 0.043 X_2
\]

Fig. 1B illustrates that only tween/cetyl ratio (X1) had a significant impact on the PDI values of the prepared nanovesicular formulations. Where the PDI values were significantly decreased with increasing the tween/cetyl ratio. This could be attributed to the efficiency of Tween 80 as a surfactant in preventing the aggregation of the prepared nanovesicles. Zambaux et al., and Ruiz et al., also assured that the increase of the surfactant

---

**Fig. 2.** Responses surface plot for the effect of tween/cetyl (T/C) ratio (X1) and chitosan % (X2) on the desirability of fluconazole nanovesicular formulation

**Fig. 3.** Fluconazole release profiles from the optimized lipotomal formula compared to the drug suspension
concentration resulted in a considerable decrease in the PDI values. The PDI is used to make sure that there is no variation in particle size. The formula that has less variation in particle size will has less PDI. **Effect of formulations factors on zeta potential (ZP)**

ZP for the prepared fluconazole nanovesicle varied from 7.25 to -2.46. As illustrated by Ahmed et al. The calculated equation for the zeta potential analysis was:

\[
ZP = 0.6492 - 1.76 X_1 - 1.49 X_2
\]  

...(3)

Figure 1C illustrates that both the independent variables X1 and X2 had no significant impact on the zeta potential of all the prepared nanovesicular formulations.

In general, the zeta potential indicates the potential stability of the colloidal system in solution. **Effect of formulations factors on encapsulation efficiency (EE)**

EE % for the prepared fluconazole nanovesicles ranged between 92.00 and 96.56 %. As illustrated by Ahmed et al. The calculated equation for the EE% analysis was:

\[
EE = 92.54 - 0.753 X_1 - 0.837 X_2 + 0.164 X_1 X_2 + 1.57 X_2^2 + 0.476 X_2^2
\]  

...(4)

Figure 1D illustrates that both the independent variables X1 and X2 had a significant impact on the EE% of all the prepared nanovesicular formulations. The EE% was

---

**Table 1. Output data of the central composite responses surface design and predicted and observed values of the optimized nanovesicular formula**

<table>
<thead>
<tr>
<th>Responses</th>
<th>PS (nm)</th>
<th>PDI</th>
<th>ZP (mV)</th>
<th>EE (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum</td>
<td>450.08 ± 7.66</td>
<td>0.152 ± 0.01</td>
<td>-2.46 ± 0.07</td>
<td>92.00 ± 1.02</td>
</tr>
<tr>
<td>Maximum</td>
<td>753.15 ± 6.24</td>
<td>1 ± 0.00</td>
<td>7.25 ± 0.68</td>
<td>96.55 ± 2.64</td>
</tr>
<tr>
<td>Model</td>
<td>Linear</td>
<td>Linear</td>
<td>Linear</td>
<td>Quadratic</td>
</tr>
<tr>
<td>P-value</td>
<td>0.0003</td>
<td>&lt; 0.0001</td>
<td>0.0697</td>
<td>0.0001</td>
</tr>
<tr>
<td>Adequate precision</td>
<td>10.97</td>
<td>17.33</td>
<td>6.35</td>
<td>18.35</td>
</tr>
<tr>
<td>Adjusted R²</td>
<td>0.762</td>
<td>0.870</td>
<td>0.295</td>
<td>0.929</td>
</tr>
<tr>
<td>Predicted R²</td>
<td>0.604</td>
<td>0.795</td>
<td>-0.402</td>
<td>0.802</td>
</tr>
<tr>
<td>R²</td>
<td>0.802</td>
<td>0.892</td>
<td>0.412</td>
<td>0.959</td>
</tr>
<tr>
<td>Significant factors</td>
<td>X₁</td>
<td>X₁</td>
<td>None</td>
<td>X₁ X₂ X₂ X₂</td>
</tr>
<tr>
<td>Observed values of optimal formulation</td>
<td>480.35</td>
<td>0.495</td>
<td>2.256</td>
<td>94.4262</td>
</tr>
<tr>
<td>Predicted values of optimal formulation</td>
<td>516.885</td>
<td>0.376</td>
<td>2.380</td>
<td>94.505</td>
</tr>
</tbody>
</table>

Presented data mean ± SD (n = 3).
decreased with increasing the tween/cetyl ratio. This could be accredited to that increasing tween concentration led to decreasing the vesicle sizes, hence decreasing the EE% due to the small inner space of the prepared vesicles. These findings are in consistency with that stated by Duong et al., who found that the EE% of the formulated vesicles were significantly decreased with increasing the surfactant concentration. Additionally, the chitosan % (X2) significantly impacted the EE% of the nanovesicles. Where the EE% was significantly decreased with increasing the chitosan %. Increasing the chitosan concentrations could result in increasing the solution viscosity which could hinder the drug entrapment. This agrees with the findings stated by Valente et al., who found that the drug EE was significantly decreased with increasing the chitosan %.

**Statistical analysis of central composite design**

The effect of the studied formulation factors on the characteristics of the prepared nanovesicles was investigated using central
composite design. Each response was investigated individually and fabricated using different order models. As displayed in Table 1, the predicted $R^2$ values of all the examined responses were in harmony with the adjusted $R^2$. A precision value higher than 4 was attained in all responses, assuring the suitability of the designed model to navigate the design space.

**Selection of the optimized Fluconazole nanovesicular formulation**

To identify the optimized nanovesicular formula, it was practically hard to provide all the needed responses at the same time, as the optimal condition met for one response may have a detrimental effect on another. However, the desirability function aggregated all desired responses in one variable to determine the optimum level of the studied factors. Figure 2 shows the highest desirability value was 0.681 for the optimized fluconazole nanovesicular formulation (F7) containing tween/cetyl ratio of 15:1 and chitosan concentration of 0.1%. This optimized formulation collectively showed the maximal PS and PDI and maximal ZP and EE%. According to the comparison of the observed and predicted values, a notable similarity was observed, as indicated in Table 1. Consequently, the nanovesicular formulation that was optimized has been selected for further investigation.

**In vitro drug release from the optimized nanovesicular formulation**

The optimized nano vesicular formulation significantly increased the Fluconazole release in comparison to the drug suspension. After 240 minutes, 57.14 % of the drug was released from the optimized formulation, while just 17.94 % of the drug was released from the drug suspension, as shown in Figure 3, with a similarity factor ($f_2$) of 33. This considerable increase in fluconazole release from the optimized nanovesicular formulation could be due to the large surface area of the prepared nanovesicles and the incorporation of tween 80 that enhanced fluconazole diffusion from the prepared vesicles to the medium.

**Microbiology test**

Fluconazole suspension and fluconazole nanovesicles MICs were determined by agar dilution, broth microdilution and GM antigen release against *Aspergillus fumigatus* ATCC 1022. *Aspergillus fumigatus* showed resistance to all concentrations of regular fluconazole by using the three methods.

The MIC obtained by broth microdilution were similar to the GM antigen release (0.5 mg/ml) as shown Figure 6. On the other hand, MIC obtained by agar dilution method show little higher (0.6 mg/ml) compared to the other two methods Figure 4.

The result of the broth microdilution method was confirmed by examining the microtiter plate under microscope x40 HPF, sign of growth was observed (hyphal conidia and conidiophores) in wells containing 0.2, 0.3, and 0.4 mg/ml Figure 5.

**CONCLUSIONS**

In this study, the optimized fluconazole nanovesicular formulation and the appropriate concentration of fluconazole nanovesicles was identified to be directly exposed to the ATCC strains of *Aspergillus fumigatus*. This is to determine the minimal dosage of the drug to be administered by the infected individuals rescuing them from the renal impairments that could occur. Finally, fluconazole nanovesicles had a better effect and lower MIC when compared to the aqueous fluconazole suspension. Considering these results obtained, the enhanced antifungal effect of fluconazole can be attributed to the promising nanocarriers provided by the optimized nanovesicular formulation.

**ACKNOWLEDGEMENT**

None to declare.

**Conflict of Interest**

All authors declared that there is no conflict of interest in this research.

**Funding Source**

This research is funded by Gulf Medical University, Ajman, UAE, grant number is GMU/COHS/GR/2019-10/003

**REFERENCES**

2. Ciecko, S. C., Scher, R. J. E. E., Nose, & Journal, T. Invasive fungal rhinitis caused by


20. Therese, K., Bagyalakshmi, R., Madhavan, H., & Deepa, P. J. I. o. m. In-vitro susceptibility testing by agar dilution method to determine the minimum inhibitory concentrations of amphotericin B, fluconazole and ketoconazole against ocular fungal isolates., 2006; 24(4), 273-279.


Paecilomyces lilacinus infection: Report of a case and a novel treatment., 2010; 89(12).


